Finn OJ[au] - Search Results

Year	Number of Results
1978	1
1979	2
1980	1
1982	2
1983	2
1984	1
1985	3
1986	1
1988	8
1989	6
1990	3
1991	3
1992	8
1993	10
1994	3
1995	5
1996	8
1997	8
1998	8
1999	2
2000	3
2001	8
2002	4
2003	4
2004	5
2005	10
2006	8
2007	7
2008	9
2009	8
2010	9
2011	7
2012	8
2013	12
2014	4
2015	3
2016	5
2017	6
2018	4
2019	3
2020	7
2021	4
2022	1

1

Beneficial autoimmunity improves cancer prognosis.

Zitvogel L, Perreault C, Finn OJ, Kroemer G. Zitvogel L, et al. Among authors: finn oj. Nat Rev Clin Oncol. 2021 Sep;18(9):591-602. doi: 10.1038/s41571-021-00508-x. Epub 2021 May 11. Nat Rev Clin Oncol. 2021. PMID: 33976418 Review.

2

Cancer immunoprevention.

Finn OJ, Beatty PL. Finn OJ, et al. Curr Opin Immunol. 2016 Apr;39:52-8. doi: 10.1016/j.coi.2016.01.002. Epub 2016 Jan 19. Curr Opin Immunol. 2016. PMID: 26799207 Free PMC article. Review.

3

Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer.

Kvorjak M, Ahmed Y, Miller ML, Sriram R, Coronnello C, Hashash JG, Hartman DJ, Telmer CA, Miskov-Zivanov N, Finn OJ, Cascio S. Kvorjak M, et al. Among authors: finn oj. Cancer Immunol Res. 2020 Feb;8(2):167-178. doi: 10.1158/2326-6066.CIR-19-0514. Epub 2019 Dec 12. Cancer Immunol Res. 2020. PMID: 31831633 Free PMC article.

4

Cancer immunology.

Melief CJ, Finn OJ. Melief CJ, et al. Among authors: finn oj. Curr Opin Immunol. 2011 Apr;23(2):234-6. doi: 10.1016/j.coi.2011.01.003. Epub 2011 Feb 1. Curr Opin Immunol. 2011. PMID: 21292460 No abstract available.

5

Cancer immunology.

Finn OJ. Finn OJ. N Engl J Med. 2008 Jun 19;358(25):2704-15. doi: 10.1056/NEJMra072739. N Engl J Med. 2008. PMID: 18565863 Review. No abstract available.

6

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. Cheever MA, et al. Among authors: finn oj. Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737. Clin Cancer Res. 2009. PMID: 19723653 Free PMC article.

7

Editorial: Myeloid Derived Suppressor Cells as Disease Modulators.

Finn OJ, Ochoa AC. Finn OJ, et al. Front Immunol. 2020 Jan 31;11:90. doi: 10.3389/fimmu.2020.00090. eCollection 2020. Front Immunol. 2020. PMID: 32082331 Free PMC article. No abstract available.

8

The dawn of vaccines for cancer prevention.

Finn OJ. Finn OJ. Nat Rev Immunol. 2018 Mar;18(3):183-194. doi: 10.1038/nri.2017.140. Epub 2017 Dec 27. Nat Rev Immunol. 2018. PMID: 29279613 Review.

9

A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Finn OJ. Finn OJ. J Immunol. 2018 Jan 15;200(2):385-391. doi: 10.4049/jimmunol.1701302. J Immunol. 2018. PMID: 29311379 Free PMC article. Review.

10

MUC1 immunotherapy is here to stay.

Kimura T, Finn OJ. Kimura T, et al. Among authors: finn oj. Expert Opin Biol Ther. 2013 Jan;13(1):35-49. doi: 10.1517/14712598.2012.725719. Epub 2012 Sep 24. Expert Opin Biol Ther. 2013. PMID: 22998452 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results